Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Company facts
| Company | Thermo Fisher Scientific Inc. |
|---|---|
| Symbol | TMO |
| Exchange | XNYS |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market cap | $223.02B (Massive market data, 2026-09-10) |
| Employees | 125,000 |
| Country | United States |
| Website | https://www.thermofisher.com |
Trading — Thermo Fisher Scientific Inc.
| Last price | $609.82 |
|---|---|
| Change | 1.10% |
| Previous close | $603.18 |
| Day range | $606.15 – $615.24 |
| 50-day average | $574.52 |
| 200-day average | $536.37 |
| Average volume | 2,135,546 |
Price basis: yfinance_daily_bar_close · 2026-09-11T20:31:40.505291+00:00
Valuation and financial health
| Earnings per share | $18.84 |
|---|---|
| Price / book | 4.23 |
| Price / cash flow | 24.75 |
| Enterprise value / EBITDA | 23.02 |
| Enterprise value / sales | 5.64 |
| Debt / equity | 0.81 |
| Current ratio | 1.55 |
| Dividend yield | 0.30% |
| Free cash flow | $7.32B |
| Cash ratio | 0.27 |
| Enterprise value | $261.51B |
Reported 2026-09-10
Earnings
| Report date | 2026-10-28 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $6.40 |
| Year-ago EPS | $5.79 |
| Analyst estimates | 8 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for TMO are on the IntelTrends dashboard.